Intellia Broadens Its Oncology Bets With CRISPR-Edited NK Cell Therapies

Partners ONK Therapeutics To Develop Five Candidates

 
• By Andrew McConaghie
  
Intellia Therpeutics
Intellia is using its CRISPR technology for in vivo and ex vivo applications, the latter focused on next-gen cancer immunotherapies. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip